Scientists have found how genetic mutations associated to Parkinson's disease may play a key role in brain cells' death, potentially paving the way for the development of more effective drug treatments.
A team of researchers from UCL, the University of Cambridge and the University of Sheffield showed how defects in the Parkinson's gene Fbxo7 cause problems with 'mitaphagy' - an essential process through which our bodies are able to get rid of damaged cells.
Mitochondria are the 'energy powerhouses' of cells. Their function is vital in nerve cells which require a great deal of energy in order to function and survive. Dysfunctional mitochondria are potentially very harmful and, normally, cells dispose of the damaged mitchondria by self-eating them, a process called mitophagy.
Most of what we know about the mitophagy process comes from the study of the familial forms of Parkinson's, one of the most common diseases of the brain. Over the last three years, two genes associated with familial Parkinson's disease, PINK1 and Parkin, have been reported to play a role in mitophagy.
The scientists showed just how central the role of mitophagy is and how mutations in Fbxo7 are also linked with the disease and interfere with the PINK1-Parkin pathway.
In people with Parkinson's, genetic mutations cause defects in mitophagy, leading to a build-up of dysfunctional mitochondria. This is likely to explain, at least partially, the death of brain cells in Parkinson's patients with these mutations.
One of the lead authors, Dr Helene Plun-Favreau from the UCL Institute of Neurology, said what makes the study so robust is the confirmation of defective mitophagy in a number of different Parkinson's models, including cells of patients who carry a mutation in the Fbxo7 gene.
Co-author Dr Heike Laman, University of Cambridge, said the study focuses the attention of the PD community on the importance of the proper maintenance of mitochondria for the health of neurons.
Professor Nicholas Wood, Neuroscience programme director for the NIHR University College London Hospitals BRC, said that it is very exciting to see how detailed biological work of this type can highlight a single pathway that contributes to Parkinson's disease.
He added that this presented the opportunity of more rationale drug design for many forms of parkinsonism.
The new study has been published in Nature Neuroscience.
